News for Marinus Pharmaceuticals, Inc. (0JYL.L)

On December 31, 2024, Vanguard Group Inc made a strategic decision to reduce its holdings in Marinus Pharmaceuticals Inc (MRNS) by 206,197 shares. This transact

PR NewswireNEW YORK, Jan. 15, 2025 NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

PR NewswireNEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

PR NewswireNEW YORK, Jan. 6, 2025 NEW YORK, Jan. 6, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

PR NewswireNEW YORK, Jan. 3, 2025 NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

NEW YORK, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

Immedica Pharma AB (Immedica), a leading global rare disease company, and [url="]Marinus Pharmaceuticals, Inc.[/url] (Nasdaq: MRNS), a pharmaceutical company c

**media[502762]**

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.33%

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Thursday. Following the market opening Thursday, the Dow traded do...

Penny stocks are defined by the Securities and Exchange Commission (SEC) as stocks that trade for less than $5 per share. They exhibit high price volatility due to their low pricing.

LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of...

Candel Therapeutics, Inc.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Growing prevalence of neurological disorders and epilepsy driving the demand for anticonvulsant drugs in the global market....

Company Continues to Deepen Executive Bench with Life Science Industry Veterans

Company Continues to Deepen Executive Bench with Life Science Industry Veterans...